Crossmark

Early transient asymptomatic neutropenia associated with alemtuzumab treatment in multiple sclerosis: a case report

Crossref DOI link: https://doi.org/10.1007/s00415-018-8976-7

Published Online: 2018-07-17

Published Print: 2018-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Galgani, Simonetta

Prosperini, Luca https://orcid.org/0000-0003-3237-6267
Haggiag, Shalom

Tortorella, Carla

Gasperini, Claudio
License Information

Text and Data Mining valid from 2018-07-17
More Information

Article History

Received: 27 June 2018

Revised: 10 July 2018

Accepted: 11 July 2018

First Online: 17 July 2018

Compliance with ethical standards

:

: SG: fees as invited speaker or travel expenses for attending meeting from Biogen, Merck-Serono, Teva, Almirall, Sanofi-Aventis, Novartis, Genzyme. LP: consulting fees from Biogen, Novartis and Roche; speaker honoraria from Biogen, Genzyme, Merck-Serono, Novartis and Teva; travel grants from Biogen, Genzyme, Novartis and Teva; research grants from the Italian MS Society (Associazione Italiana Sclerosi Multipla) and Genzyme. SH: reports no disclosures. CT: honoraria for speaking and travel grant from Biogen, Sanofi-Aventis, Merck-Serono, Bayer-Schering, Teva, Genzyme, Almirall and Novartis. CG: fees as invited speaker or travel expenses for attending meeting from Biogen, Merck-Serono, Teva, Sanofi, Novartis, Genzyme.

: The patient provided informed oral and written consent in accordance with specific national laws and the ethics standards laid down in the 1964 Declaration of Helsinki and its later amendments.